Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer

  • Authors:
    • Bo Yin
    • Mo Zhang
    • Yu Zeng
    • Youqiang Li
    • Chao Zhang
    • Yongsheng Song
  • View Affiliations

  • Published online on: February 17, 2016     https://doi.org/10.3892/ijo.2016.3396
  • Pages: 1730-1736
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Paclitaxel frequently serves as the first-line chemotherapeutic agent for castration-resistant prostate cancer (PCa) patients. However, acquired paclitaxel-resistance almost always occurs after initial responses, and the mechanisms by which this occurs remain largely unknown. The goal of the present study was to identify differentially expressed protein(s) associated with paclitaxel-resistance and further explore the potential mechanisms involved in drug resistance. By comparing the nuclear matrix protein (NMP) patterns of DU145-TxR cells, the previously established stable paclitaxel-resistant PCa cells, with that of the parental DU145 cells using two-dimensional electrophoresis, we found that cytokeratin 18 (CK18) is downregulated in DU145-TxR cells. The downregulation of CK18 in DU145-TxR cells at mRNA, NMP and total cellular protein levels was validated by real-time RT-PCR, immunoblotting and immunofluorescence, indicating that the downregulation of CK18 was a global effect in DU145-TxR cells due to paclitaxel-resistance. Furthermore, in vivo assay of xenograft transplantation confirmed the higher tumorigenicity of DU145-TxR cells, suggesting that these paclitaxel-resistant PCa cells possessed potent cancer stem cell (CSC)-like properties and eventually developed paclitaxel-resistance. Moreover, we determined by immunohistochemistry that CK18 expression in PCa tissues was inversely correlated with tumor grade in a statistically significant fashion, indicating a potential association of the downregulation of CK18 with tumor aggressiveness. Therefore, further study to define the potential role of CK18 may lead to novel therapy strategies as well as clinically useful biomarker for PCa patients.

References

1 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Debes JD and Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 351:1488–1490. 2004. View Article : Google Scholar : PubMed/NCBI

3 

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI

4 

Madan RA, Pal SK, Sartor O and Dahut WL: Overcoming chemotherapy resistance in prostate cancer. Clin Cancer Res. 17:3892–3902. 2011. View Article : Google Scholar : PubMed/NCBI

5 

Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004. View Article : Google Scholar : PubMed/NCBI

6 

Inoue T, Leman ES, Yeater DB and Getzenberg RH: The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer. Prostate. 68:1048–1056. 2008. View Article : Google Scholar : PubMed/NCBI

7 

Zeng Y, Kulkarni P, Inoue T and Getzenberg RH: Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity. J Cell Biochem. 107:179–188. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Li Y, Zeng Y, Mooney SM, Yin B, Mizokami A, Namiki M and Getzenberg RH: Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells. J Cell Biochem. 112:2125–2137. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Pederson T: Half a century of ‘the nuclear matrix’. Mol Biol Cell. 11:799–805. 2000. View Article : Google Scholar : PubMed/NCBI

10 

Getzenberg RH, Konety BR, Oeler TA, Quigley MM, Hakam A, Becich MJ and Bahnson RR: Bladder cancer-associated nuclear matrix proteins. Cancer Res. 56:1690–1694. 1996.PubMed/NCBI

11 

Partin AW, Getzenberg RH, CarMichael MJ, Vindivich D, Yoo J, Epstein JI and Coffey DS: Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res. 53:744–746. 1993.PubMed/NCBI

12 

Brünagel G, Vietmeier BN, Bauer AJ, Schoen RE and Getzenberg RH: Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer Res. 62:2437–2442. 2002.PubMed/NCBI

13 

Leman ES and Getzenberg RH: Nuclear structure as a source of cancer specific biomarkers. J Cell Biochem. 104:1988–1993. 2008. View Article : Google Scholar

14 

Seruga B, Ocana A and Tannock IF: Drug resistance in meta-static castration-resistant prostate cancer. Nat Rev Clin Oncol. 8:12–23. 2011. View Article : Google Scholar

15 

Kim JJ, Yin B, Christudass CS, Terada N, Rajagopalan K, Fabry B, Lee DY, Shiraishi T, Getzenberg RH, Veltri RW, et al: Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer. J Cell Biochem. 114:1286–1293. 2013. View Article : Google Scholar

16 

Shevchenko A, Wilm M, Vorm O and Mann M: Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem. 68:850–858. 1996. View Article : Google Scholar : PubMed/NCBI

17 

Yin B, Zeng Y, Wang X, Liu G, Zhang M and Song Y: Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma. Int J Clin Exp Pathol. 7:4112–4119. 2014.PubMed/NCBI

18 

Yin B, Liu G, Wang XS, Zhang H, Song YS and Wu B: Expression profile of cancer-testis genes in transitional cell carcinoma of the bladder. Urol Oncol. 30:886–892. 2012. View Article : Google Scholar

19 

Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI

20 

Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, Zagorac S, Alcala S, Rodriguez-Arabaolaza I, Ramirez JC, et al: Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell. 9:433–446. 2011. View Article : Google Scholar : PubMed/NCBI

21 

Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI

22 

Schutte B, Henfling M, Kölgen W, Bouman M, Meex S, Leers MP, Nap M, Björklund V, Björklund P, Björklund B, et al: Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res. 297:11–26. 2004. View Article : Google Scholar : PubMed/NCBI

23 

Moll R, Franke WW, Schiller DL, Geiger B and Krepler R: The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell. 31:11–24. 1982. View Article : Google Scholar : PubMed/NCBI

24 

Linder S, Olofsson MH, Herrmann R and Ulukaya E: Utilization of cytokeratin-based biomarkers for pharmacodynamic studies. Expert Rev Mol Diagn. 10:353–359. 2010. View Article : Google Scholar : PubMed/NCBI

25 

Knapp AC and Franke WW: Spontaneous losses of control of cytokeratin gene expression in transformed, non-epithelial human cells occurring at different levels of regulation. Cell. 59:67–79. 1989. View Article : Google Scholar : PubMed/NCBI

26 

Woelfle U, Sauter G, Santjer S, Brakenhoff R and Pantel K: Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res. 10:2670–2674. 2004. View Article : Google Scholar : PubMed/NCBI

27 

Kirfel J, Magin TM and Reichelt J: Keratins: A structural scaffold with emerging functions. Cell Mol Life Sci. 60:56–71. 2003. View Article : Google Scholar : PubMed/NCBI

28 

Paramio JM and Jorcano JL: Beyond structure: Do intermediate filaments modulate cell signalling? BioEssays. 24:836–844. 2002. View Article : Google Scholar : PubMed/NCBI

29 

Parekh H, Wiesen K and Simpkins H: Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol. 53:461–470. 1997. View Article : Google Scholar : PubMed/NCBI

30 

Liang Y, Meleady P, Cleary I, McDonnell S, Connolly L and Clynes M: Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness. Eur J Cancer. 37:1041–1052. 2001. View Article : Google Scholar : PubMed/NCBI

31 

Yin B, Yang Y, Zhao Z, Zeng Y, Mooney SM, Li M, Xu X, Song Y, Wu B and Yang Z: Arachidonate 12-lipoxygenase may serve as a potential marker and therapeutic target for prostate cancer stem cells. Int J Oncol. 38:1041–1046. 2011. View Article : Google Scholar : PubMed/NCBI

32 

van der Horst G, Bos L and van der Pluijm G: Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol Cancer Res. 10:995–1009. 2012. View Article : Google Scholar : PubMed/NCBI

33 

Yin B, Zeng Y, Liu G, Wang X, Wang P and Song Y: MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells. Int J Clin Exp Pathol. 7:2934–2941. 2014.PubMed/NCBI

34 

Barak V, Goike H, Panaretakis KW and Einarsson R: Clinical utility of cytokeratins as tumor markers. Clin Biochem. 37:529–540. 2004. View Article : Google Scholar : PubMed/NCBI

35 

Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, et al: Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res. 13:3198–3206. 2007. View Article : Google Scholar : PubMed/NCBI

36 

Demiray M, Ulukaya EE, Arslan M, Gokgoz S, Saraydaroglu O, Ercan I, Evrensel T and Manavoglu O: Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: A prospective pilot study. Cancer Invest. 24:669–676. 2006. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2016
Volume 48 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yin, B., Zhang, M., Zeng, Y., Li, Y., Zhang, C., & Song, Y. (2016). Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer. International Journal of Oncology, 48, 1730-1736. https://doi.org/10.3892/ijo.2016.3396
MLA
Yin, B., Zhang, M., Zeng, Y., Li, Y., Zhang, C., Song, Y."Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer". International Journal of Oncology 48.4 (2016): 1730-1736.
Chicago
Yin, B., Zhang, M., Zeng, Y., Li, Y., Zhang, C., Song, Y."Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer". International Journal of Oncology 48, no. 4 (2016): 1730-1736. https://doi.org/10.3892/ijo.2016.3396